Weekly growth hormone therapy safely improves long-term height

Children with growth hormone deficiency had a reduction in treatment-related adverse events over time and nearly reached a height standard deviation score of 0 with once-weekly somatrogon-ghla, according to long-term study data. As Healio previously reported, the FDA approved somatrogon-ghla (Ngenla, Opko Health/Pfizer) for children with growth failure due to inadequate secretion of endogenous GH